Literature DB >> 16084258

Antituberculosis drug resistance and anonymous HIV surveillance in tuberculosis patients in Botswana, 2002.

L J Nelson1, E A Talbot, M J Mwasekaga, P K Ngirubiu, R A Mwansa, M Notha, C D Wells.   

Abstract

Two surveys undertaken in Botswana in the 1990s have recorded low rates of antituberculosis drug resistance, despite a three-fold rise in tuberculosis since 1989. We undertook a third survey to determine both trends since 1995 and HIV prevalence in tuberculosis patients in Botswana. Sputum specimens were obtained from patients nationwide in 2002 who also underwent anonymous, rapid HIV testing by use of Oraquick. Of 2200 sputum smear-positive patients and 219 previously treated patients with suspected recurrent tuberculosis, 1457 (60%) were infected with HIV. Resistance to at least one drug in new patients rose from 16 (3.7%) isolates in 1995 to 123 (10.4%; p<0.0001) in 2002. Interventions for tuberculosis control are urgently needed in Botswana to prevent further emergence of drug resistance.

Entities:  

Mesh:

Year:  2005        PMID: 16084258     DOI: 10.1016/S0140-6736(05)67062-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  19 in total

1.  Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis-Human Immunodeficiency Virus Coinfection in South Africa.

Authors:  James C M Brust; N Sarita Shah; Koleka Mlisana; Pravi Moodley; Salim Allana; Angela Campbell; Brent A Johnson; Iqbal Master; Thuli Mthiyane; Simlatha Lachman; Lee-Megan Larkan; Yuming Ning; Amyn Malik; Jonathan P Smith; Neel R Gandhi
Journal:  Clin Infect Dis       Date:  2018-04-03       Impact factor: 9.079

2.  Increase in anti-tuberculosis drug resistance in Botswana: results from the fourth National Drug Resistance Survey.

Authors:  H J Menzies; G Moalosi; V Anisimova; V Gammino; C Sentle; M A Bachhuber; E Bile; K Radisowa; O Kachuwaire; J Basotli; T Maribe; R Makombe; J Shepherd; B Kim; T Samandari; S El-Halabi; J Chirenda; K P Cain
Journal:  Int J Tuberc Lung Dis       Date:  2014-09       Impact factor: 2.373

3.  Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosis.

Authors:  Shruthi Ravimohan; Neo Tamuhla; Andrew P Steenhoff; Rona Letlhogile; Didimalang Kgomotso Makutu; Kebatshabile Nfanyana; Tumelo Rantleru; Ann Tierney; Kelebogile Nkakana; Adam B Schwartz; Robert Gross; Rob Roy Macgregor; Scarlett L Bellamy; Ian Frank; Drew Weissman; Gregory P Bisson
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

Review 4.  Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis.

Authors:  Keertan Dheda; Tawanda Gumbo; Neel R Gandhi; Megan Murray; Grant Theron; Zarir Udwadia; G B Migliori; Robin Warren
Journal:  Lancet Respir Med       Date:  2014-03-24       Impact factor: 30.700

5.  Tuberculosis, drug resistance, and HIV/AIDS: a triple threat.

Authors:  Gerald Friedland
Journal:  Curr Infect Dis Rep       Date:  2007-05       Impact factor: 3.725

6.  Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana.

Authors:  J Hafkin; C Modongo; C Newcomb; E Lowenthal; R R MacGregor; A P Steenhoff; H Friedman; G P Bisson
Journal:  Int J Tuberc Lung Dis       Date:  2013-01-14       Impact factor: 2.373

Review 7.  Epidemiology and treatment of multidrug resistant tuberculosis.

Authors:  Carole D Mitnick; Sasha C Appleton; Sonya S Shin
Journal:  Semin Respir Crit Care Med       Date:  2008-09-22       Impact factor: 3.119

8.  Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana.

Authors:  L K Shipton; C W Wester; S Stock; N Ndwapi; T Gaolathe; I Thior; A Avalos; H J Moffat; J J Mboya; E Widenfelt; M Essex; M D Hughes; R L Shapiro
Journal:  Int J Tuberc Lung Dis       Date:  2009-03       Impact factor: 2.373

9.  Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.

Authors:  Sekai Chideya; Carla A Winston; Charles A Peloquin; William Z Bradford; Philip C Hopewell; Charles D Wells; Arthur L Reingold; Thomas A Kenyon; Themba L Moeti; Jordan W Tappero
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

10.  Underreported threat of multidrug-resistant tuberculosis in Africa.

Authors:  Yanis Ben Amor; Bennett Nemser; Angad Singh; Alyssa Sankin; Neil Schluger
Journal:  Emerg Infect Dis       Date:  2008-09       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.